Home Services Singulex Enters into Partnershipwith QIAGEN to Develop Companion Diagnostics;

Singulex Enters into Partnershipwith QIAGEN to Develop Companion Diagnostics;


News: Qiagen NV (NASDAQ:QGEN) belongs to Services  sector and Research Services industry. Singulex, Inc. as of late pronounced that it has come to an arranged partnershipwith QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) concentrated on the improvement of friend diagnostics. Through the joint effort, QIAGEN will have admittance to Singulex’s Single Molecule Counting immunodiagnostic stage, adding extra immunoassay abilities to QIAGEN’s current atomic testing administrations for the advancement of friend diagnostics. In Addition To, QIAGEN will have admittance to Singulex’s CLIA-authorized research center.

Singulex will furnish QIAGEN with access to its exclusive SMCTM immunodiagnostics stage, and the organizations mean to work together in a scope of illness applications.

“As the Next Generation Immunodiagnostics organization, this arranged association is another verification point for the adaptability of Singulex’s high-affectability SMC innovation,” said Guido Baechler, President and Chief Executive Officer of Singulex. “We are glad to team up with QIAGEN and anticipate our cooperate.”

Singulex trusts the partnershipwith QIAGEN will extend the get to and usage of its restrictive SMC stage and is a vital approval of high-affectability immunoassays and its flexibility of uses. SMC is in no time accessible by means of Singulex’s CLIA-authorized research center, with future application through the SGX ClarityTM System, a completely computerized IVD stage in a matter of seconds being developed and not yet endorsed available to be purchased.

Summary: Singulex is the cutting edge immunodiagnostic organization creating Single Molecule Counting innovation for clinical diagnostics and logical revelation. Singulex’s restrictive SMCTM innovation encourages doctors and researchers to identify biomarkers of sickness that were in the past imperceptible. Controlled by SMC innovation, Singulex’s ultrasensitive lab testing administrations are changing patient care from receptive ailment treatment to proactive wellbeing organization.